All In Biotech

NDA 213005 · Liquidia Tech

Yutrepia

Treprostinil Sodium · Inhalation

Last checked: Nov 19, 2026Latest source record: May 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

May 23, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

129

42 Phase 3, 15 recruiting

FAERS reports

10,115

6,803 serious, 1,369 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 8, 2025.

• Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). ( 1.2 ) 1.1 Pulmonary Arterial Hypertension YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities. While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration [see Clinical Studies ( 14 )] . 1.2 Pulmonary Hypertension Associated with ILD YUTREPIA is indicated for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to...

Mechanism: The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 23, 2025 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabel
4 products under this application
  • YUTREPIA · TREPROSTINIL SODIUM EQ 0.0795MG BASE/INH · POWDER, INHALATION · Prescription
  • YUTREPIA · TREPROSTINIL SODIUM EQ 0.0265MG BASE/INH · POWDER, INHALATION · Prescription
  • YUTREPIA · TREPROSTINIL SODIUM EQ 0.106MG BASE/INH · POWDER, INHALATION · Prescription
  • YUTREPIA · TREPROSTINIL SODIUM EQ 0.053MG BASE/INH · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Treprostinil" as an intervention, any sponsor and status, largest first.

All 129 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea2,186
  • headache2,024
  • cough1,793
  • diarrhoea1,558
  • nausea1,323
  • dizziness1,227
  • fatigue1,199
  • hypotension812
  • death744
  • oxygen saturation decreased692
  • vomiting646
  • malaise559

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20063
20071
20082
20098
201013
201122
201240
201342
201471
2015146
201690
2017103
2018101
2019456
2020481
2021623
2022865
20231,150
20241,046
20251,754
20263,097

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 116 on PubMed

Sponsor: Liquidia Tech

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.